TO STUDY THE EFFECT OF SANGUINARIA CANADENSIS & FORM GROUP SYMPTOMS OF PAPAVERACEAE FAMILY FROM VARIOUS BOOKS.

STUDY OF PAPAVERACEAE FAMILY WITH SPECIAL EMPHASIS ON SANGUINARIA CANADENSIS.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/05/052861

Enrollment

Registered

2023-05-18

Start date

Unknown

Completion date

Unknown

Last updated

2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R688- Other general symptoms and signs

Interventions

Intervention1: HOMEOPATHY REMEDY: MEDICINE WILL BE SELECT ON BASIS OF TOTALLY SYMPTOMS OF SANQUINARIA CANADENAIS IN A SINGLE DOSE. THE POTENCY AND REPITATION OF MEDICINE AS PER REQUIREMENTS OF CASES.

Eligibility

Inclusion criteria

Inclusion criteria: CASES WHICH ARE ACUTE AND CHRONIC IN NATURE CASES WHERE SANGUINARIA CANADENSIS WILL BE INDICATED THROUGH SYMPTOMS TOTALITY PATIENT BETWEEN AGE OF 10 TO 80 YEARS

Exclusion criteria

Exclusion criteria: CASES WHERE SANGUINARIA CANADENSIS WILL NOT BE INDICATED THROUGH SYMPTOMS TOTALITY PATIENT WITH CONGENITAL ANOMALY PATIENTS WITH SEVERE SYSTEMATIC AND IRREVERSIBLE PATHOLOGY CASES OF PREGNANT WOMEN

Design outcomes

Secondary

Measure	Time frame
TO CLINICALLY VERIFY TOTALITY OF SANGUINARIA CANADENSISTimepoint: BEFORE AND AFTER TREATMENT	—

Primary

Measure	Time frame
MYMOP SCORETimepoint: EVERY 3,4,7,15,21,30DAYS OR AS PER REQUIRMENTS OF CASES	—

Countries

India

Contacts

Public ContactKAJAL DHIRAJLAL SENTA

DR V H DAVE HOMEOPATHIC MEDICAL COLLEGE

dr.sonal2705@gmail.com9426432585

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026